Drugs / thrombin
thrombin
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00591916 | Jan 2006 → Nov 2010 | — | The University of Texas Medical Branch, Galveston | Withdrawn | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02802995 | May 2016 → May 2017 | chronic ulcer of skin | University of Witwatersrand, South Africa | Terminated | No outcome recorded |
| Phase 3 | NCT01717612 | Oct 2012 → Apr 2016 | esophageal varices, gastric ulcer | National Science and Technology Council, Taiwan | Unknown | No outcome recorded |
| Phase 3 | NCT01662856 | Aug 2012 → Dec 2015 | vascular hemostatic disease | Grifols | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07644923 | Aug 2026 → Aug 2028 expected | — | NYU Langone Health | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04814433 | Mar 2021 → Jul 2023 | — | NYU Langone Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00290836 | May 2004 → Aug 2007 | — | Nycomed | Completed | No outcome recorded |
| Phase not applicable1 trial · 1 missed | ||||||
| — | NCT04602689 | Oct 2020 → Jul 2022 | gastric adenoma, gastric carcinoma | Seoul National University Hospital | Completed | Missed primary |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT06175676 Comparator | Dec 2021 → Jun 2023 | chronic dacryocystitis | Tianjin Medical University Eye Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT06302582 Background | Feb → Nov 2024 | decubitus ulcer | Liaocheng People's Hospital | Unknown | No outcome recorded |
| — | NCT04403503 Comparator | Jul 2018 → Feb 2019 | — | Hacettepe University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | thrombin | “Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).” NCT01662856 ↗9“Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD” NCT04602689 ↗ “gelatin sponge sheet covered with thrombin and tobramycin and dexamethasone ophthalmic ointment” NCT06175676 ↗ “PRP gel (PRP+thrombin mixture, 2ml)” NCT06302582 ↗ |
| Known as | Recombinant Human Thrombin | “Recombinant human thrombin is available as 5000-unit and 20,000-unit vials of sterile recombinant topical thrombin lyophilized powder for solution.” NCT04814433 ↗ |
| Known as | Thrombin, Bovine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04403503 ↗ |
| Action | Restore | “The regular application of exogenous PRP and Thrombin, to chronic wounds, restores the autocrine feedback loop of tissue repair” NCT02802995 ↗ |
| Modality | Protein / enzyme biologic | “Human fibrinogen/thrombin and bovine aprotinin” NCT00290836 ↗ |
| Route | Other | “thrombin injection” NCT01717612 ↗ |